DOCSLIB.ORG

Imaging and Properties of Extrasynaptic Gabaa Receptors in the Brain

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Imaging and Properties of Extrasynaptic Gabaa Receptors in the Brain IMAGING AND PROPERTIES OF EXTRASYNAPTIC GABAA RECEPTORS IN THE BRAIN Saku Sinkkonen Institute of Biomedicine, Pharmacology University of Helsinki, Finland and Turku Graduate School of Biomedical Sciences and Department of Pharmacology and Clinical Pharmacology University of Turku, Finland ACADEMIC DISSERTATION To be presented, with the permission of the Medical Faculty of the University of Helsinki, for public examination in the Small Lecture Hall of Haartman Institute, Haartmaninkatu 3, on November 5th, 2004, at 12 o’clock. Helsinki 2004 Supervised by Professor Esa R. Korpi, M.D. Institute of Biomedicine, Pharmacology Faculty of Medicine University of Helsinki, Finland Reviewed by Associate Professor Bryndis Birnir, Ph.D. Department of Physiological Sciences Faculty of Medicine University of Lund, Sweden and Docent Petteri Piepponen, Ph.D. (Pharm.) Department of Pharmacology and Toxicology Faculty of Pharmacy University of Helsinki, Finland Dissertation opponent Professor Emeritus Simo S. Oja, M.D., Ph.D., M.LL. Brain Research Center Medical School University of Tampere, Finland ISBN 952-91-7825-5 (paperback) ISBN 952-10-2092-X (PDF http://ethesis.helsinki.fi) University Printing House Helsinki 2004 To Wera 4 TABLE OF CONTENTS ABSTRACT.............................................................................................................................. 7 ORIGINAL COMMUNICATIONS ......................................................................................... 8 ABBREVIATIONS...................................................................................................................9 1. INTRODUCTION............................................................................................................... 11 2. REVIEW OF THE LITERATURE..................................................................................... 14 2.1. GABA as neurotransmitter......................................................................................... 14 2.2. GABA receptors......................................................................................................... 14 2.3. GABAA receptor structure.......................................................................................... 15 2.3.1. Subunit genes ................................................................................................. 15 2.3.2. Subunit proteins.............................................................................................. 16 2.3.3. Receptor assembly.......................................................................................... 16 2.3.4. Heterologous receptor expression .................................................................. 17 2.3.5. Receptor subtypes in the native brain ............................................................ 19 2.4. GABAA receptor function .......................................................................................... 19 2.4.1. Phasic inhibition............................................................................................. 21 2.4.2. Tonic inhibition.............................................................................................. 22 2.4.3. Inhibition in the cerebellar granule cell layer................................................. 24 2.4.4. Inhibition in the hippocampus........................................................................ 26 2.5. Molecular pharmacology of GABAA receptor binding sites...................................... 27 2.5.1. GABA............................................................................................................. 28 2.5.2. Picrotoxinin/TBPS ......................................................................................... 29 2.5.3. Benzodiazepines............................................................................................. 31 2.5.4. DMCM ........................................................................................................... 32 2.5.5. Furosemide..................................................................................................... 33 2.6. Tiagabine.................................................................................................................... 34 2.7. GABAA receptors in disease ...................................................................................... 34 2.7.1. Anxiety........................................................................................................... 34 2.7.2. Epilepsy.......................................................................................................... 35 2.8. GABAAergic drug therapy and its problems.............................................................. 38 3. AIMS OF THE STUDY...................................................................................................... 39 4. MATERIALS AND METHODS........................................................................................ 40 4.1. Experimental animals................................................................................................. 40 4.2. Ligand autoradiographic assays (I, II, III, IV, V) ...................................................... 40 4.2.1. Preparation of brain sections (I, II, III, IV, V) ............................................... 40 4.2.2. [35S]TBPS binding (I, II, III, IV, V)............................................................... 41 4.2.3. [3H]Ro 15-4513 binding (I, III, IV)................................................................ 41 4.2.4. [3H]Muscimol binding (I, III)......................................................................... 42 4.3. Localization of GABAA receptor subunits by in situ hybridization (II) .................... 42 4.4. Quantitative autoradiographic film analysis (I, II, III, IV, V).................................... 43 4.5. Recombinant GABAA receptors in HEK 293 cells (III) ............................................ 43 4.5.1. Receptor expression ....................................................................................... 43 4.5.2. [35S]TBPS binding assay................................................................................ 44 4.6. Electrophysiological recordings from acutely isolated mouse hippocampal CA1 pyramidal cells (IV) ................................................................................................... 44 5 4.7. Determination of receptor subunit composition (IV)................................................. 44 4.7.1. Preparation of receptor extracts...................................................................... 44 4.7.2. Immunoaffinity chromatography ................................................................... 44 4.7.3. Quantification of GABAA receptor subtypes by immunoprecipitation and [3H]muscimol binding assays......................................................................... 45 4.8. Mouse behavioral studies (IV) ................................................................................... 45 4.8.1. Observational functional analysis by the SHIRPA protocol.......................... 45 4.8.2. Light-dark choice test..................................................................................... 46 4.8.3. T-maze test ..................................................................................................... 46 4.8.4. Convulsion tests ............................................................................................. 47 4.9. Recombinant GABAA receptors in Xenopus oocytes (V).......................................... 47 4.9.1. Receptor expression ....................................................................................... 47 4.9.2. Electrophysiological recordings..................................................................... 47 4.10. Statistics (I, II, III, IV, V)......................................................................................... 48 5. RESULTS AND DISCUSSION ......................................................................................... 49 5.1. Development of a receptor autoradiographic method to reveal GABA-insensitive [35S]TBPS binding (I).................................................................. 49 5.2. Localization and prevalence of GABA-insensitive [35S]TBPS binding in the brain (I, II)........................................................................................................ 52 5.3. Roles of different GABAA receptor subunits in GABA-insensitive [35S]TBPS binding...................................................................................................... 53 5.3.1. Correlation with receptor subunit mRNA localization by in situ hybridization................................................................................................... 53 5.3.1.1. Adult rat (II) ....................................................................................... 53 5.3.1.2. Developing rat.................................................................................... 54 5.3.2. GABA-insensitive [35S]TBPS binding in genetically engineered mouse lines..................................................................................................... 54 5.3.2.1. The β3 subunit knockout mice (β3-/-) (II) ......................................... 54 5.3.2.2. The δ subunit knockout mice (δ-/-) (II) ............................................. 56 5.3.2.3. The α6 subunit knockout mice (α6-/-) (II) ........................................ 56 5.3.2.4. Mice with ectopic α6 subunit expression (Thy1α6) (IV) .................
Load more

Recommended publications
  • Picrotoxin-Like Channel Blockers of GABAA Receptors
    COMMENTARY Picrotoxin-like channel blockers of GABAA receptors Richard W. Olsen* Department of Molecular and Medical Pharmacology, Geffen School of Medicine, University of California, Los Angeles, CA 90095-1735 icrotoxin (PTX) is the prototypic vous system. Instead of an acetylcholine antagonist of GABAA receptors (ACh) target, the cage convulsants are (GABARs), the primary media- noncompetitive GABAR antagonists act- tors of inhibitory neurotransmis- ing at the PTX site: they inhibit GABAR Psion (rapid and tonic) in the nervous currents and synapses in mammalian neu- system. Picrotoxinin (Fig. 1A), the active rons and inhibit [3H]dihydropicrotoxinin ingredient in this plant convulsant, struc- binding to GABAR sites in brain mem- turally does not resemble GABA, a sim- branes (7, 9). A potent example, t-butyl ple, small amino acid, but it is a polycylic bicyclophosphorothionate, is a major re- compound with no nitrogen atom. The search tool used to assay GABARs by compound somehow prevents ion flow radio-ligand binding (10). through the chloride channel activated by This drug target appears to be the site GABA in the GABAR, a member of the of action of the experimental convulsant cys-loop, ligand-gated ion channel super- pentylenetetrazol (1, 4) and numerous family. Unlike the competitive GABAR polychlorinated hydrocarbon insecticides, antagonist bicuculline, PTX is clearly a including dieldrin, lindane, and fipronil, noncompetitive antagonist (NCA), acting compounds that have been applied in not at the GABA recognition site but per- huge amounts to the environment with haps within the ion channel. Thus PTX major agricultural economic impact (2). ͞ appears to be an excellent example of al- Some of the other potent toxicants insec- losteric modulation, which is extremely ticides were also radiolabeled and used to important in protein function in general characterize receptor action, allowing and especially for GABAR (1).
    [Show full text]
  • ANNNNNNNNNNNNNNNNNNNN 100A 006 Left Eye Input Right Eye Input
    US 20190175049A1 ( 19) United States (12 ) Patent Application Publication (10 ) Pub. No. : US 2019 /0175049 A1 Welling ( 43 ) Pub . Date : Jun . 13 , 2019 ( 54 ) TECHNIQUES FOR ANALYZING (52 ) U . S . CI. NON -VERBAL MARKERS OF CONDITIONS CPC . .. A61B 5 /04842 (2013 . 01 ) ; A61B 5 / 7289 USING ELECTROPHYSIOLOGICAL DATA (2013 . 01) ; A61B 5 /0478 ( 2013 .01 ) ; A61B 5 /7225 ( 2013. 01 ) ; G06N 20 / 10 (2019 .01 ) (71 ) Applicant: Massachusetts Institute of Technology , Cambridge , MA (US ) ( 57 ) ABSTRACT (72 ) Inventor : Caroline Welling, Hanover, NH (US ) Embodiments related to analyzing brain activity of a subject to identify signs associated with binocular rivalry . Sensed ( 21 ) Appl. No. : 16 / 206, 639 electrical activity of a subject' s brain is received over a time period while the subject is exposed to a visual stimulus. The ( 22 ) Filed : Nov. 30 , 2018 sensed electrical activity comprises a first frequency band Related U . S . Application Data associated with a first frequency of a first image presented to the subject ' s left eye , a second frequency band associated (60 ) Provisional application No .62 / 593 , 535, filed on Dec . with a second frequency of a second image presented to the 1 , 2017 subject ' s right eye . A set of events in the time period is determined based on the frequency bands, wherein an event Publication Classification is associated with a change from a previous perceptual event (51 ) Int. Ci. to a new perceptual event. A metric for the subject is A61B 5 /0484 ( 2006 .01 ) determined based on the set of events . The metric is ana A61B 5 /00 ( 2006 .01 ) lyzed to determine whether the subject exhibits signs asso GO6N 20 / 10 (2006 .01 ) ciated with a condition that is associated with binocular A61B 5 /0478 ( 2006 .01 ) rivalry .
    [Show full text]
  • Campro Catalog Stable Isotope
    Introduction & Welcome Dear Valued Customer, We are pleased to present to you our Stable Isotopes Catalog which contains more than three thousand (3000) high quality labeled compounds. You will find new additions that are beneficial for your research. Campro Scientific is proud to work together with Isotec, Inc. for the distribution and marketing of their stable isotopes. We have been working with Isotec for more than twenty years and know that their products meet the highest standard. Campro Scientific was founded in 1981 and we provide services to some of the most prestigious universities, research institutes and laboratories throughout Europe. We are a research-oriented company specialized in supporting the requirements of the scientific community. We are the exclusive distributor of some of the world’s leading producers of research chemicals, radioisotopes, stable isotopes and environmental standards. We understand the requirements of our customers, and work every day to fulfill them. In working with us you are guaranteed to receive: - Excellent customer service - High quality products - Dependable service - Efficient distribution The highly educated staff at Campro’s headquarters and sales office is ready to assist you with your questions and product requirements. Feel free to call us at any time. Sincerely, Dr. Ahmad Rajabi General Manager 180/280 = unlabeled 185/285 = 15N labeled 181/281 = double labeled (13C+15N, 13C+D, 15N+18O etc.) 186/286 = 12C labeled 182/282 = d labeled 187/287 = 17O labeled 183/283 = 13C labeleld 188/288 = 18O labeled 184/284 = 16O labeled, 14N labeled 189/289 = Noble Gases Table of Contents Ordering Information.................................................................................................. page 4 - 5 Packaging Information ..............................................................................................
    [Show full text]
  • Picrotoxinin and Diazepam Bind to Two Distinct Proteins: Further Evidence That Pentobarbital May Act at the Picrotoxinin Site1
    0270~6474/81/0109-1036$02.00/O The Journal of Neuroscience Copyright 0 Society for Neuroscience Vol. 1, No. 9, pp. 1036-1042 Printed in U.S.A. September 1981 PICROTOXININ AND DIAZEPAM BIND TO TWO DISTINCT PROTEINS: FURTHER EVIDENCE THAT PENTOBARBITAL MAY ACT AT THE PICROTOXININ SITE1 WILLIAM C. DAVIS AND MAHARAJ K. TICKU2 Division of Molecular Pharmacology, Department of Pharmacology, The University of Texas Health Science Center at San Antonio, San Antonio. Texas 78284 Abstract a-[3H]Dihydropicrotoxinin (DHP) and [3H]diazepam binding proteins were solubilized from rat brain membranes with 1% Lubrol-Px. Gel filtration of the Lubrol-solubilized fraction revealed that [3H]DHP and [3H]diazepam bind to two distinct peaks with apparent molecular weights of 185,000 and 61,000, respectively. The signal-to-noise ratio of [3H]DHP binding to 185,000-dalton fractions was improved significantly. [3H]DHP bound to the 185,000-dalton fraction with two binding constants. Muscimol and pentobarbital, while enhancing [3H]diazepam binding to membrane and crude Lubrol-solubilized fractions, failed to enhance [3H]diazepam binding to the 61,000-dalton fraction. Pentobarbital inhibited the binding of [3H]DHP to the 185,000-dalton fraction with an IC5” value of 60 + 12 PM. The binding of [3H]DHP also was inhibited by several depressant and convulsant drugs which affect y-aminobutyric acid (GABA)-mediated transmission. These results provide strong evidence that picrotoxinin and diazepam bind to two distinct proteins and that pentobarbital may act at the picrotoxinin-sensitive site of the benzodiazepine . GABA receptor. ionophore complex. The y-aminobutyric acid (GABA) receptor system ap- Olsen, 1978, 1979; Olsen et al., 1979).
    [Show full text]
  • 5994392 Tion of Application No. 67375.734 Eb3-1685, PEN. T
    USOO5994392A United States Patent (19) 11 Patent Number: 5,994,392 Shashoua (45) Date of Patent: Nov.30, 1999 54 ANTIPSYCHOTIC PRODRUGS COMPRISING 5,120,760 6/1992 Horrobin ................................. 514/458 AN ANTIPSYCHOTICAGENT COUPLED TO 5,141,958 8/1992 Crozier-Willi et al. ................ 514/558 AN UNSATURATED FATTY ACID 5,216,023 6/1993 Literati et al. .......................... 514/538 5,246,726 9/1993 Horrobin et al. ....................... 424/646 5,516,800 5/1996 Horrobin et al. ....................... 514/560 75 Inventor: Victor E. Shashoua, Brookline, Mass. 5,580,556 12/1996 Horrobin ................................ 424/85.4 73 Assignee: Neuromedica, Inc., Conshohocken, Pa. FOREIGN PATENT DOCUMENTS 30009 6/1981 European Pat. Off.. 21 Appl. No.: 08/462,820 009 1694 10/1983 European Pat. Off.. 22 Filed: Jun. 5, 1995 09 1694 10/1983 European Pat. Off.. 91694 10/1983 European Pat. Off.. Related U.S. Application Data 59-025327 2/1984 Japan. 1153629 6/1989 Japan. 63 Continuation of application No. 08/080,675, Jun. 21, 1993, 1203331 8/1989 Japan. abandoned, which is a continuation of application No. 07/952,191, Sep. 28, 1992, abandoned, which is a continu- (List continued on next page.) ation of application No. 07/577,329, Sep. 4, 1990, aban doned, which is a continuation-in-part of application No. OTHER PUBLICATIONS 07/535,812,tion of application Jun. 11, No. 1990, 67,375.734 abandoned, Eb3-1685, which is a continu-PEN. T. Higuchi et al. 66 Prodrugs as Noye Drug Delivery Sys 4,933,324, which is a continuation-in-part of application No.
    [Show full text]
  • Developmental Deltamethrin: Effects on Cognition, Neurotransmitter Systems, Inflammatory Cytokines and Cell Death
    Developmental deltamethrin: Effects on cognition, neurotransmitter systems, inflammatory cytokines and cell death A dissertation submitted to the Graduate School of the University of Cincinnati In partial fulfillment of the requirements for the degree of Doctor of Philosophy In the Neuroscience Graduate Program of the College of Medicine By Emily Pitzer B.S. Westminster College April 2020 Dissertation Committee: Steve Danzer, Ph.D. Mary Beth Genter, Ph.D. Gary Gudelsky, Ph.D. Kimberly Yolton, Ph.D. Charles Vorhees, Ph.D. (Advisor) Michael Williams, Ph.D. (Chair) ABSTRACT Deltamethrin (DLM) is a Type II pyrethroid pesticide and is more widely used with the elimination of organophosphate pesticides. Epidemiological studies have linked elevated levels of pyrethroid metabolites in urine during development with neurological disorders, raising concern for the safety of children exposed to these agents. Few animal studies have explored the effects or mechanisms of DLM-induced deficits in behavior and cognition after developmental exposure. The aim of the present work is to examine the long-term effects of developmental (postnatal day (P) 3-20) DLM exposure in Sprague-Dawley rats on behavior, cognition, and cellular outcomes. First, the developmental effects of early DLM exposure on allocentric and egocentric learning and memory, locomotor activity, startle, conditioned freezing, and anxiety-like behaviors were assessed. The developmental effects of DLM on long-term potentiation (LTP) at P25-35, on adult dopamine (DA) release, monoamine levels, and mRNA levels of receptors/transporters/channels were then determined. In follow-up experiments, adult LTP, hippocampal glutamate release, terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) staining for cell death, as well as DA and glutamate receptors, proinflammatory cytokines, and caspase-3 for protein expression were assessed.
    [Show full text]
  • 解 説 GABA Synapse
    日 本 農 薬 学 会 誌10, 555-567 (1985) 解 説 GABA支 配 の 神 経 シ ナ ッ プ ス -殺 虫 剤 の タ ー ゲ ッ ト?- 田 中 啓 司 三共株式会社農薬研究所 (昭和60年5月20日 受理) GABA Synapse: A Target Site of Insecticides? Keiji TANAKA Agricultural Chemicals Research Laboratories, Sanhyo Co., Ltd., Yasu-cho, Yasu-gun, Shiga 520-23, Japan やavermectin8)の 出現 で あ る. は じ め に 節 足 動 物 に お け るGABAの 作 用 1950年 に γ-aminobutyric acid (GABA) が マ ウス脳 か ら単 離 同 定1,2)さ れ てか ら, そ の 神 経 伝 達 物 質 と し て Usherwoodら9, 10)は, 昆 虫 の抑 制 性 の神 経 一筋 接 合 部 の 歴 史 が 始 ま る. しか し, 長 い間, この ア ミノ酸 の脳 内 位 でGABAが 当 時 構 造 未 知 で あ った 抑 制 性 の神 経 伝 達 で の 作 用 は 不 明 の まま で, た ん にご代 謝 産 物 で あ ろ うと考 物 質 と 同様 にご作 用 す る こ とを 見 い だ した. GABAは 抑 制 え られ た 時 が あ った ほ どで あ る3). そ の 薬理 作用 が 発 見 性 神 経 が 入 りこ んで い る 筋 線 維 膜 の"input"コ ン ダ ク され た の は 哺 乳動 物 で は な く, 甲殻 類 を用 い て の研 究 で, タ ンス を 増 加 させ る.
    [Show full text]
  • Toxicity and Mode of Action of Avermectin B1 Against Insects Terence Simon Corbitt, B.Sc. a Thesis Submitted for the Degree of D
    1 Toxicity and Mode of Action of Avermectin B1 against insects Terence Simon Corbitt, B.Sc. A Thesis Submitted for the degree of Doctor of Philosophy of the University of London and for the Diploma of Membership of Imperial College. Department of Pure and Applied Biology Imperial College Silwood Park Ascot, Berkshire SL5 7PY August 1987 2 ACKNOWLEDGEMENTS I would like to thank my supervisor Dr. D.J. Wright for his supervision and advice during the course of this work and presentation of this thesis. I would also like to thank the following: Dr A. Green (Merck Sharp and Dohme, New Jersey) for helpful advice and donation of [3H]AVMB1 and AVMB-j, Drs J. Hardie, D.J.Galley, M. Djamgoz and Mr I. Fosbrook for advice and help given during this study. Thanks also to Ms S.Smith of TDRI, Porton, Wilts, for the Spodoptera 1i ttorali s, and to Mr T.Carty of the Institute of Virology, Oxford for the Heliothis armigera cultures. This work was carried out with the aid of a grant from the Science and Engineering Research Council. Insect culture was carried out under MAFF licence No. PHF 909/52 (116). I would like to thank my parents for their interest and continual support during my education. Thanks also to Tom for plant culture, Sarah for typing my tables, Chris Addison and other friends who made my stay at Silwood Park enjoyable. I would like to say a special thank you to Tanya for her help and friendship. This thesis is dedicated to my wife Anne for her support and understanding during the preparation of this work.
    [Show full text]
  • O'neill2020 Redacted.Pdf (7.617Mb)
    This thesis has been submitted in fulfilment of the requirements for a postgraduate degree (e.g. PhD, MPhil, DClinPsychol) at the University of Edinburgh. Please note the following terms and conditions of use: This work is protected by copyright and other intellectual property rights, which are retained by the thesis author, unless otherwise stated. A copy can be downloaded for personal non-commercial research or study, without prior permission or charge. This thesis cannot be reproduced or quoted extensively from without first obtaining permission in writing from the author. The content must not be changed in any way or sold commercially in any format or medium without the formal permission of the author. When referring to this work, full bibliographic details including the author, title, awarding institution and date of the thesis must be given. Functional Characterisation of Spontaneously Active GABAA Receptors in Rat Dentate Gyrus Granule Cells Nathanael O’Neill B.Medsc. (Hons) Doctor of Philosophy The University of Edinburgh 2020 ii Abstract GABAA receptors (GABAARs) are the principal inhibitory neurotransmitter receptors in the adult mammalian central nervous system. GABAARs mediate two forms of inhibition: fast, phasic conductance; and slow, tonic conductance. Tonic conductance arises due to the persistent activation of GABAARs. This persistent activation can occur by GABA-dependent or GABA- independent mechanisms. Low concentrations of ambient GABA activate high affinity GABAARs located outside the synapse – at peri-/extra-synaptic sites – to generate GABA-dependent tonic conductance. In contrast, GABA-independent tonic conductance is generated by GABAARs that activate spontaneously, in the absence of GABA, due to constitutive receptor gating.
    [Show full text]
  • The Gabaa Receptor 8 Subunit Gene Promoter Fragments to Direct Long - Term Neuron - Specific Expression
    THE GABAa RECEPTOR 8 SUBUNIT GENE PROMOTER : CHARACTERISATION AND USE Alexa Brett Roberts Division of Molecular Genetics Institute of Biomedical and Life Sciences University of Glasgow Glasgow A dissertation submitted for the degree of Doctor of Philosophy of the University of Glasgow February 1998 ProQuest Number: 13818612 All rights reserved INFORMATION TO ALL USERS The quality of this reproduction is dependent upon the quality of the copy submitted. In the unlikely event that the author did not send a com plete manuscript and there are missing pages, these will be noted. Also, if material had to be removed, a note will indicate the deletion. uest ProQuest 13818612 Published by ProQuest LLC(2018). Copyright of the Dissertation is held by the Author. All rights reserved. This work is protected against unauthorized copying under Title 17, United States C ode Microform Edition © ProQuest LLC. ProQuest LLC. 789 East Eisenhower Parkway P.O. Box 1346 Ann Arbor, Ml 48106- 1346 GIASGOW UNIVERSITY LIBRARY 11110 (coh O f GLASGOW 1 IUNIVERSITT I [LQgAW I For my husband Stuart and for my children Ross and Ailie with love Also to JR (Grandad) in loving memory Preface The work presented in this thesis was performed entirely by the author, except where acknowledged. I declare that my thesis contains unique work and will not be submitted for any other degree, diploma or qualification at any other University. A. Brett Roberts December 1997 Acknowledgements I would like to thank Professor R.W. Davies for giving me the opportunity to study for this degree and for his help throughout the last three years.
    [Show full text]
  • Tonic Gabaergic Inhibition As a New Way to Regulate Mesolimbic Dopamine System
    Tonic GABAergic inhibition as a new way to regulate mesolimbic dopamine system Elena Vashchinkina Institute of Biomedicine, Pharmacology University of Helsinki Academic Dissertation To be presented with the permission of the Medical Faculty of the University of Helsinki, for public examination in lecture hall 3, Biomedicum Helsinki 1, Haartmaninkatu 8, on December 13th 2013 at 12 noon Helsinki 2013 Supervisor Professor Esa R. Korpi, MD PhD Institute of Biomedicine, Pharmacology Faculty of Medicine University of Helsinki, Finland Reviewers Docent Mikko Airavaara, PhD Institute of Biotechnology University of Helsinki, Finland Docent Tarja Stenberg, MD PhD Institute of Biomedicine, Physiology University of Helsinki, Finland Dissertation Opponent Professor Kimmo Jensen, MD PhD Department of Biomedicine Aarhus University, Denmark ISBN 978-952-10-9636-5 (paperback) ISBN 978-952-10-9637-2 (PDF) http://ethesis.helsinki.fi Unigrafia OY Helsinki 2013 TABLE OF CONTENTS Abstract ......................................................................................................................... 1 Original publications ................................................................................................... 2 Abbreviations ............................................................................................................... 3 Glossary of terms ......................................................................................................... 4 1 INTRODUCTION ....................................................................................................
    [Show full text]
  • Neuroscience Products
    Neuroscience Products CATALOG CATALOG NUMBER U.S. $ NUMBER U.S. $ -A- 3-(N-ACETYLAMINO)-5-(N-DECYL-N- 1 mg 27.50 159549 METHYLAMINO)BENZYL ALCOHOL 5 mg 89.40 o A23187 0-5 C [103955-90-4] (ADMB) See: Antibiotic A23187 A Protein Kinase C activator. Ref.: Proc. Nat. Acad. Sci. USA, 83, 4214 AA-861 20 mg 72.70 (1986). 159061 Purity: 95% 100 mg 326.40 C20H34N2O2 MW 334.5 0oC Orally active, specific and potent inhibitor of 5-lipoxygenase. N-ACETYL-ASP-GLU 25 mg 45.00 153036 [3106-85-2] 100 mg 156.00 Ref.: 1. Yoshimoto, T., et.al., Biochim. o Biophys. Acta, 713, 470 (1982). 2. Ashida, -20-0 C An endogenous neuropeptide with high 250 mg 303.65 Y., et.al., Prostaglandins, 26, 955 (1983). 3. affinity for a brain "Glutamate" receptor. Ancill, R.J., et.al., J. Int. Med. Res., 18, 75 Ref: Zaczek, R., et al., Proc. Natl. Acad. (1990). Sci. (USA), 80, 1116 (1983). C21H26O3 MW 326.4 C11H16N2O8 MW 304.3 ABL PROTEIN TYROSINE KINASE 250 U 47.25 N-ACETYL-2-BENZYLTRYPTAMINE 195876 (v-abl) 1 KU 162.75 See: Luzindole -70oC Recombinant Expressed in E. coli ACETYL-DL-CARNITINE 250 mg 60.00 A truncated form of the v-abl protein 154690 [2504-11-2] 1 g 214.00 tyrosine kinase which contains the 0oC Hydrochloride minimum region needed for kinase activity Crystalline and fibroblast transformation. Suppresses C9H17NO4 • HCl MW 239.7 apoptosis and induces resistance to anti-cancer compounds. O-ACETYL-L-CARNITINE CHLORIDE 500 mg 11.45 Activity: 100 KU/ml 159062 [5080-50-2] 1 g 20.65 Unit Definition: one unit is the amount of 0-5oC (R-(-)-2-Acetyloxy-3-carboxy-N,N,N-trimethyl 5 g 97.45 enzyme which catalyzes the transfer of 1 -1-propanaminium chloride) pmol of phosphate to EAIYAAPFAKKK per Purity: >88% minute at 30°C, pH 7.5.
    [Show full text]